📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. (2024)

First Author: Cevik M

Attributed to: Tuberculosis Treatment Trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(24)00223-8

PubMed Identifier: 38768617

Publication URI: http://europepmc.org/abstract/MED/38768617

Type: Journal Article/Review

Volume: 24

Parent Publication: The Lancet. Infectious diseases

Issue: 9

ISSN: 1473-3099